Elekta’s Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities for Elekta Unity enables clinicians to use enhanced adaptive radiation therapy workflow to accurately deliver the treatment
Elekta Unity - Full Room Side View. (Credit: Elekta)
Swedish medical technology company Elekta has received the US Food and Drug Administration (FDA) 510(k) approval for additional features on its Elekta Unity MR-Linac.
The US regulator approved the use of Comprehensive Motion Management (CMM) with True Tracking and automatic gating for Elekta Unity MR-Linac.
With the additional features, Elekta Unity can continuously calculate the movement of the tumour located anywhere in the body and automatically records the data.
The new features enable clinicians to use enhanced adaptive radiation therapy workflow to accurately deliver the treatment to moving organs, said the company.
Elekta Americas region executive vice president Carlos Castilleja said: “We have the privilege to be working in radiotherapy, a field that helps people at their most vulnerable moment in life.
“To know that we can now bring a technology to the US that really moves the needle in cancer care gives me and my whole team great satisfaction. We believe MR-guided therapy is going to play a major role in radiotherapy moving forward.
“This is evidenced by a large hospital network in New Jersey that is in the process of setting up three Elekta Unity systems, in addition to the more than 100 systems ordered or in use in the US and around the world.”
The CMM supports four workflows for managing the treatment of targets, including two free breathing workflows that prevent the patients from holding their breath.
It leverages integrated predictive algorithms to enhance the accuracy of the management of breathing motion, with no additional set-up time, or hardware to install.
CMM also enables clinicians to rapidly shift the beam to record systematic changes in the target position during the treatment session without re-imaging.
Elekta Unity MR-Linac with CMM enables clinicians to customise their motion management strategy to the specific needs of their patients, said the medical device maker.
University of Miami radiation oncology vice chair Lorraine Portelance said: “Improving the accuracy of beam delivery is the key to increasing the therapeutic window in radiotherapy.
“But of course, to truly improve accuracy we have to both track the motion and be able to quickly respond to it. These new motion management features do that and was a big reason we have decided to invest in this system.”